Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes.

Q2 Medicine

Clinical Diabetes Pub Date : 2024-01-01 Epub Date: 2023-08-28 DOI:10.2337/cd23-0025

Carol J Levy, Dan Raghinaru, Yogish C Kudva, Keta Pandit, Thomas Blevins, Luis Casaubon, Donna Desjardins, Camilla M Levister, Grenye O'Malley, Corey Reid, John Lum, Craig Kollman, Roy W Beck

引用次数: 0

Abstract

The t:slim X2 insulin pump with Control-IQ technology (Control-IQ) advanced hybrid closed-loop automated insulin delivery system was evaluated in this prospective single-arm trial. Thirty adults with type 2 diabetes using the Control-IQ system showed substantial glycemic improvement with no increase in hypoglycemia. Mean time in range (70-180 mg/dL) improved 15%, representing an increase of 3.6 hours/day, and mean glucose decreased by 22 mg/dL.

查看原文本刊更多论文

控制- iq自动胰岛素输送对2型糖尿病患者基础注射和仅基础注射胰岛素的有益影响

在这项前瞻性单臂试验中，对采用Control IQ技术（Control IQ）的t:slim X2胰岛素泵进行了评估。使用Control IQ系统的30名患有2型糖尿病的成年人血糖显著改善，低血糖症没有增加。在范围（70–180 mg/dL）内的平均时间改善了15%，即每天增加3.6小时，平均葡萄糖减少了22 mg/dL。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Diabetes Medicine-Internal Medicine

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： The mission of Clinical Diabetes is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. Clinical Diabetes is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.